This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dote, H. Articles by Tofilon, P. J. Search for Related Content PubMed PubMed Citation Articles by Dote, H. Articles by Tofilon, P. J.

Inhibition of Hsp90 Compromises the DNA Damage Response to Radiation

¹ Molecular Radiation Therapeutics and ² Radiation Oncology Branches, National Cancer Institute, Bethesda, Maryland; ³ Science Applications International Corporation-Frederick, National Cancer Institute-Frederick, Frederick, Maryland; and ⁴ Department of Interdisciplinary Oncology, Drug Discovery Program, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, Florida

Requests for reprints: Philip J. Tofilon, Department of Interdisciplinary Oncology, Drug Discovery Program, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, SRB2-DRDIS, Tampa, FL 33612. Phone: 813-745-2268; Fax: 813-745-6748; E-mail: tofilopj{at}moffitt.usf.edu.

Inhibitors of the molecular chaperone Hsp90 have been shown to enhance tumor cell radiosensitivity. To begin to address the mechanism responsible, we have determined the effect of the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17DMAG) on the DNA damage response to radiation. Exposure of MiaPaCa tumor cells to 17DMAG, which results in radiosensitization, inhibited the repair of DNA double-strand breaks according to H2AX foci dispersal and the neutral comet assay. This repair inhibition was associated with reduced DNA-PK catalytic subunit (DNA-PKcs) phosphorylation after irradiation and a disruption of DNA-PKcs/ErbB1 interaction. These data suggest that the previously established 17DMAG-mediated reduction in ErbB1 activity reduces its interaction with DNA-PKcs and thus accounts for the attenuation of radiation-induced DNA-PK activation. 17DMAG was also found to abrogate the activation of the G₂- and S-phase cell cycle checkpoints. Associated with these events was a reduction in radiation-induced ataxia-telangiectasia mutated (ATM) activation and foci formation in 17DMAG-treated cells. Although no interaction between ATM and Hsp90 was detected, Hsp90 was found to interact with the MRE11/Rad50/NBS1 (MRN) complex. 17DMAG exposure reduced the ability of the MRN components to form nuclear foci after irradiation. Moreover, 17DMAG exposure reduced the interaction between NBS1 and ATM, although no degradation of the MRN complex was detected. These results suggest that the diminished radiation-induced activation of ATM in 17DMAG-treated cells was the result of a compromise in the function of the MRN complex. These data indicate that Hsp90 can contribute to the DNA damage response to radiation affecting both DNA repair and cell cycle checkpoint activation. (Cancer Res 2006; 66(18): 9211-20)

This article has been cited by other articles:

				F. A. Dungey, K. W. Caldecott, and A. J. Chalmers Enhanced radiosensitization of human glioma cells by combining inhibition of poly(ADP-ribose) polymerase with inhibition of heat shock protein 90 Mol. Cancer Ther., August 1, 2009; 8(8): 2243 - 2254. [Abstract] [Full Text] [PDF]

				C. MOSER, S. A. LANG, and O. STOELTZING Heat-shock Protein 90 (Hsp90) as a Molecular Target for Therapy of Gastrointestinal Cancer Anticancer Res, June 1, 2009; 29(6): 2031 - 2042. [Abstract] [Full Text] [PDF]

				A. M. McCord, M. Jamal, U. T. Shankavarum, F. F. Lang, K. Camphausen, and P. J. Tofilon Physiologic Oxygen Concentration Enhances the Stem-Like Properties of CD133+ Human Glioblastoma Cells In vitro Mol. Cancer Res., April 1, 2009; 7(4): 489 - 497. [Abstract] [Full Text] [PDF]

				C. M.-E. Sauvageot, J. L. Weatherbee, S. Kesari, S. E. Winters, J. Barnes, J. Dellagatta, N. R. Ramakrishna, C. D. Stiles, A. L.-J. Kung, M. W. Kieran, et al. Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells Neuro-oncol, January 1, 2009; 11(2): 109 - 121. [Abstract] [Full Text] [PDF]

				U. Banerji Heat Shock Protein 90 as a Drug Target: Some Like It Hot Clin. Cancer Res., January 1, 2009; 15(1): 9 - 14. [Abstract] [Full Text] [PDF]

				P. Chinnaiyan, D. Cerna, W. E. Burgan, K. Beam, E. S. Williams, K. Camphausen, and P. J. Tofilon Postradiation Sensitization of the Histone Deacetylase Inhibitor Valproic Acid Clin. Cancer Res., September 1, 2008; 14(17): 5410 - 5415. [Abstract] [Full Text] [PDF]

				T. T. Koll, S. S. Feis, M. H. Wright, M. M. Teniola, M. M. Richardson, A. I. Robles, J. Bradsher, J. Capala, and L. Varticovski HSP90 inhibitor, DMAG, synergizes with radiation of lung cancer cells by interfering with base excision and ATM-mediated DNA repair Mol. Cancer Ther., July 1, 2008; 7(7): 1985 - 1992. [Abstract] [Full Text] [PDF]

				K. Camphausen and P. J. Tofilon Inhibition of Hsp90: A Multitarget Approach to Radiosensitization Clin. Cancer Res., August 1, 2007; 13(15): 4326 - 4330. [Abstract] [Full Text] [PDF]

				J. T.-C. Chang, S.-H. Chan, C.-Y. Lin, T.-Y. Lin, H.-M. Wang, C.-T. Liao, T.-H. Wang, L.-Y. Lee, and A.-J. Cheng Differentially expressed genes in radioresistant nasopharyngeal cancer cells: gp96 and GDF15 Mol. Cancer Ther., August 1, 2007; 6(8): 2271 - 2279. [Abstract] [Full Text] [PDF]

				T. Oda, T. Hayano, H. Miyaso, N. Takahashi, and T. Yamashita Hsp90 regulates the Fanconi anemia DNA damage response pathway Blood, June 1, 2007; 109(11): 5016 - 5026. [Abstract] [Full Text] [PDF]